Composite end points of death and hospitalization are the only appropriate option for most trials.
INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux; Nancy, France.
Ichraq
I
Latar
INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du Cœur et des Vaisseaux. Electronic address: nicolas_girerd@yahoo.com.
Nicolas
N
Girerd
D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000401:mortality* / Q000628:therapy*; D008297:Male; D018570:Risk Assessment / Q000379:methods*